BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company developing novel antibacterial products for serious infections caused by multidrug-resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, held from September 14-16, 2026, in New York City. The presentation is a key opportunity for the company to communicate its strategic vision and recent advancements to the investment community.
Chief Financial Officer Hernan Levett will deliver the live session on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, Chief Executive Officer Dr. Marc Gitzinger will provide an on-demand presentation that goes live on September 11, 2026, at 7:00 AM ET, with a replay available for 90 days. This dual format ensures broad accessibility for investors unable to attend in person. The webcast will be accessible through the H.C. Wainwright platform and the BioVersys website in the investor section.
The conference appearance underscores BioVersys' commitment to addressing the urgent global health threat of antimicrobial resistance (AMR). The company's pipeline is built on two proprietary technology platforms: TRIC and Ansamycin Chemistry. These platforms enable the development of candidates designed to overcome resistance mechanisms, block virulence production, and directly target pathogenic bacteria, offering new hope in the fight against life-threatening resistant infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
BioVersys' lead programs target nosocomial infections caused by Acinetobacter baumannii (BV100, in Phase 3) and tuberculosis (alpibectir, in Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium from the University of Lille, France). These programs highlight the company's focus on areas with high unmet medical need. The Phase 3 trial for BV100 is particularly significant given the rise of carbapenem-resistant Acinetobacter baumannii, which the World Health Organization has listed as a critical priority pathogen.
The presentation at the H.C. Wainwright conference provides BioVersys with a platform to attract potential investors and partners, which is crucial for advancing its late-stage clinical trials. The company's participation also signals its confidence in its pipeline and its strategy to bring much-needed treatments to market. With antimicrobial resistance causing an estimated 1.27 million deaths directly in 2019, according to a study in The Lancet, the successful development of new antibiotics is of paramount importance.
BioVersys is headquartered in Basel, Switzerland, a leading biotech hub. The company's leadership will be available for one-on-one meetings with registered attendees during the conference, offering an opportunity for deeper engagement with interested parties. Those unable to attend can access the on-demand presentation via the provided links.
For more information about BioVersys and its pipeline, visit the company's website.
